Drug intelligence / Profile preview

pseudomonas aeruginosa vaccine

Development stage
Phase 3
Lead developer
IBSS Biomed
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular, Subcutaneous
01

Overview

Pseudovac is a polyvalent, inactivated bacterial vaccine developed and manufactured by IBSS Biomed (Biomed Lublin). It is indicated for the prevention and adjunctive treatment of infections caused by *Pseudomonas aeruginosa*, particularly in high-risk populations such as patients with extensive burns, chronic wounds, or those undergoing major surgical procedures. The vaccine is composed of a suspension of seven inactivated strains of *P. aeruginosa*, selected to represent the most prevalent serotypes (based on the Habs classification system). Upon administration, Pseudovac stimulates the host's immune system to produce specific protective antibodies against the bacteria, providing active immunization to prevent colonization, localized infection, and systemic complications such as sepsis.

Brand names
Pseudovac
Other names
Polyvalent Pseudomonas vaccineSzczepionka przeciw pseudomonasPseudomonas aeruginosa vaccine (inactivated)
02

Targets

P. aeruginosa LPS (Pseudomonas aeruginosa lipopolysaccharide)OprM (Outer membrane protein OprM)P. aeruginosa (Pseudomonas aeruginosa)

Beyond the preview

Go deeper on pseudomonas aeruginosa vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on pseudomonas aeruginosa vaccine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call